A Non-Randomized, Open-Label, Exploratory Mechanistic Validation (PoM) Clinical Trial of LV232 Capsule Assessing Serotonin Transporter Occupancy in the Healthy Adult Brain Using 11C-DASB Positron Emission Tomography (PET)
Latest Information Update: 16 Jun 2025
At a glance
- Drugs LV 232 (Primary) ; Escitalopram
- Indications Major depressive disorder
- Focus Pharmacokinetics
- Sponsors Vigonvita Life Sciences
Most Recent Events
- 10 Jun 2025 Status changed from recruiting to completed.
- 28 Feb 2025 Planned number of patients changed from 8 to 16.
- 14 Feb 2025 Planned End Date changed from 1 Dec 2024 to 1 May 2025.